What are research peptides?

Research peptides are short chains of amino acids — the same building blocks as proteins — synthesized in laboratory settings for use in scientific investigations. Unlike larger protein therapeutics, peptides are typically 2–50 amino acids in length, which confers unique pharmacokinetic properties including targeted receptor binding, relatively rapid degradation, and low immunogenicity. Preclinical studies explore their roles in signaling pathways across metabolic, regenerative, and neuroendocrine systems.

What is a Certificate of Analysis (COA)?

A Certificate of Analysis is a document issued by an accredited analytical laboratory confirming the identity, purity, and potency of a synthesized compound. For research peptides, a COA typically includes HPLC chromatograms, mass spectrometry data, amino acid composition analysis, and solubility data. Independent third-party COAs — generated by labs with no financial relationship to the supplier — are considered the gold standard for verifying compound quality in preclinical research.

What is BPC-157 and what biological mechanisms have been studied?

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Research has examined its effects on angiogenesis, nitric oxide synthesis, and growth factor receptor modulation. Proposed mechanisms include upregulation of vascular endothelial growth factor (VEGF), interaction with the NO-system to promote vasodilation, and modulation of the dopaminergic and serotonergic neurotransmitter systems. Preclinical studies across rodent models report accelerated tendon-to-bone healing, muscle injury repair, and gastroprotective effects.

What is TB-500 (Thymosin Beta-4) and how does it relate to actin dynamics?

TB-500 is a synthetic version of the 43-amino acid peptide Thymosin Beta-4 (Tβ4), one of the most abundant peptides in mammalian cells. Its primary structural role is the sequestration of globular actin (G-actin), which regulates actin polymerization dynamics essential for cell migration, proliferation, and wound healing. Research has demonstrated that Tβ4 promotes the migration of keratinocytes and endothelial cells into wound sites, stimulates angiogenesis, and reduces inflammation via down-regulation of NF-κB signaling.

What is MOTS-c and how does it relate to mitochondrial signaling?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. It activates AMP-activated protein kinase (AMPK), a central energy-sensing enzyme. Research in mouse models has shown that MOTS-c administration improves insulin sensitivity, reduces high-fat-diet-induced obesity, and extends median lifespan in aged mice. Circulating MOTS-c levels decline with age in humans, making it a subject of longevity research.

What is SS-31 and what is its proposed role in mitochondrial membrane protection?

SS-31 (elamipretide) is a tetrapeptide that selectively partitions into the inner mitochondrial membrane and binds cardiolipin — a lipid essential for cristae structure and the organization of respiratory chain supercomplexes — thereby reducing electron leak, superoxide generation, and cytochrome c release. Animal models of heart failure and ischemia-reperfusion injury have demonstrated improvements in ATP production and reductions in oxidative stress with SS-31 treatment.

What is Retatrutide and what receptor systems does it target?

Retatrutide (LY3437943) is a tri-agonist peptide that activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Published phase 2 clinical trial data (NEJM, 2023) reported mean body-weight reductions of approximately 17% over 24 weeks at the highest dose studied.

How are synthetic peptides stored to maintain stability?

Lyophilized (freeze-dried) peptides are the most stable form for long-term storage. In powder form, most synthetic peptides remain stable for 12–24 months when stored at −20 °C in a desiccated, light-protected environment. Reconstitution with sterile bacteriostatic water — which contains 0.9% benzyl alcohol as a preservative — allows repeated use from a single vial over several weeks when refrigerated at 2–8 °C.

CJC-1295 + Ipamorelin: Research Overview

CJC-1295 + Ipamorelin is a combination of two mechanistically distinct growth hormone secretagogues: CJC-1295, a GHRH analog, and Ipamorelin, a selective ghrelin-receptor (GHSR) agonist. The pair is studied for synergistic, pulsatile growth hormone release.

Two complementary mechanisms

CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH) that binds and activates GHRH receptors in the pituitary. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic — that stimulates GH release through a separate receptor pathway, without significantly affecting cortisol or prolactin. Because they act on the two primary regulatory inputs to pituitary somatotrophs, they are studied together.

Synergistic GH release research

Preclinical research indicates that simultaneous GHRH-receptor and GHSR activation produces GH pulses greater than either compound alone, while preserving the physiological pulsatility (high nocturnal pulses, lower daytime levels) that distinguishes this approach from continuous exogenous growth hormone. This finding has informed the study of pituitary-axis regulation and age-related GH decline.

GHRH analog vs. exogenous HGH

A recurring theme in this research area is the contrast between GHRH-stimulated GH and recombinant human growth hormone. GHRH analogs prompt the pituitary to secrete its own GH while maintaining negative feedback through somatostatin, whereas exogenous HGH delivers a sustained, non-pulsatile elevation that bypasses normal regulation. The relative merits remain an active area of endocrinological research.

Frequently asked questions

What is the CJC-1295 + Ipamorelin combination and why are they studied together?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) stabilized by DAC (drug affinity complex) technology, which significantly extends its plasma half-life by forming a covalent bond with albumin. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a ghrelin mimetic — that stimulates pituitary GH release through a separate receptor pathway. Combining GHRH analog and GHSR agonist targets both primary regulatory inputs to pituitary somatotrophs, producing synergistic GH pulses in preclinical studies that are larger than either peptide alone while maintaining the physiological pulsatility that distinguishes this approach from continuous exogenous GH administration.

Source: J Clin Endocrinol Metab (2006) · PubMed

What distinguishes a GHRH analog from exogenous HGH in terms of GH release?

Exogenous recombinant human growth hormone (rhGH) delivers a sustained, non-pulsatile elevation of circulating GH that bypasses normal hypothalamic-pituitary regulation. In contrast, GHRH analogs stimulate the pituitary to secrete its own GH in response to the hypothalamic signal, preserving pulsatility (high nocturnal pulses, lower daytime levels) and maintaining negative feedback through somatostatin. This physiological pattern is thought to reduce risks associated with continuous GH excess, including insulin resistance and IGF-1 overshoot. The relative benefit of GHRH-stimulated GH versus exogenous GH is an active area of endocrinological research.

Source: Endocr Rev (2018) · PubMed

How does the GH/IGF-1 axis change with aging?

The somatotropic axis undergoes progressive decline with aging — a process termed somatopause. After peak GH secretion in late adolescence, mean 24-hour GH levels decline approximately 14% per decade, with corresponding reductions in IGF-1 and downstream anabolic signaling. This age-related decline correlates with increased visceral adiposity, decreased lean mass, reduced bone density, and impaired sleep architecture. Research has examined whether restoring youthful GH pulsatility through GHRH analogs or GH secretagogues could attenuate these changes, though the benefit-risk profile — particularly with respect to insulin resistance and potential neoplastic risk — remains under investigation.

Source: J Endocrinol (2013) · PubMed

How is peptide purity measured and why does it matter?

Peptide purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry. These techniques quantify the proportion of the target compound relative to impurities such as deletion sequences, oxidized variants, or solvent residues. Research applications require high purity — commonly ≥98% — to ensure that observed biological effects can be attributed to the intended molecule rather than contaminants. Independent third-party certificates of analysis (COAs) provide an objective record of purity at the time of synthesis.

Source: J Pept Sci (2019) · PubMed

View CJC-1295 + Ipamorelin in the catalog →